Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs . Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data
Anticancer Research · 2024
DOI: 10.21873/anticanres.16809 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Anticancer Research, 2024. Verfasst von Sarah Sharman Moser und 5 weiteren Autor:innen. Beteiligte Einrichtung: Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel; moser_sa@mac.org.il. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel; moser_sa@mac.org.il.
- Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel.
- Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- The School of Pharmacy, Joseph Banks Laboratories, University of Lincoln, Lincoln, U.K.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Institute of Oncology, Rambam Medical Centre, Haifa, Israel.
Zitieren
APA
Moser, S. S., Apter, L., Solomon, J., Chodick, G., Wollner, M., & Siegelmann-Danieli, N. (2024). Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs . Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data. Anticancer Research. https://doi.org/10.21873/anticanres.16809
Vancouver
Moser SS, Apter L, Solomon J, Chodick G, Wollner M, Siegelmann-Danieli N. Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs . Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data. Anticancer Research. 2024. doi:10.21873/anticanres.16809
BibTeX
@article{Moser2024,
author = {Moser, Sarah Sharman and Apter, Lior and Solomon, Josie and Chodick, Gabriel and Wollner, Miriana and Siegelmann-Danieli, Nava},
title = {Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs . Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.16809}
}
EUVIMED